See Accompanying Notes to Condensed Consolidated Financial Statements

GENUFOOD ENERGY ENZYMES CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(US$, except share data and per share data, or otherwise noted)

See Accompanying Notes to Condensed Consolidated Financial Statements

GENUFOOD ENERGY ENZYMES CORP

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – GENERAL ORGANIZATION AND BUSINESS

Genufood Energy Enzymes Corp., USA (the “Company” or “GEEC”) was incorporated under the laws of the State of Nevada on June 21, 2010. The Company is a start-up company that is engaged in the business of promoting, marketing, distributing and exporting sea water nasal spray for human consumption in Taiwan and USA. The Company plans to set up a subsidiary in Taiwan and explore this market during 2020 once the relevant approval and permits about its nasal spray products are obtained from the Taiwan health authorities. The Company’s strategy is to market its nasal spray product in both Taiwan and USA through online (e.g. internet-based platforms) or offline channels (e.g. both retail and wholesale outlets).

The following is a summary of the history background of the Company:

On May 24, 2011, GEEC Internet Sales (Private) Limited (“GEECIS”), a wholly-owned subsidiary of GEEC, was established in the Democratic Socialist Republic of Sri Lanka. GEECIS was established initially to be responsible for GEEC’s internet sales worldwide, but its role changed to that of a sole country distributor. On August 8, 2013, GEECIS changed the company name from GEEC Internet Sales (Private) Limited to Genufood Enzymes Lanka (Private) Limited (“GELPL”).

On February 13, 2012 GEEC incorporated a wholly-owned subsidiary company, Genufood Enzymes (S) Pte Ltd (“GESPL”) in Singapore with a view to be the sole country distributor for certain enzymes products in Singapore.

In 2014, GEEC incorporated a wholly-owned subsidiary, Genufood Enzymes (Thailand) Co., Ltd. (“GETCL”), in Thailand.

On August 19, 2014, GEEC entered into a share exchange agreement with Natfresh Beverages Corp (“Natfresh”) pursuant to which shareholders of Natfresh were issued one share of GEEC common stock for each share of Natfresh stock. As a result of the share exchange, Natfresh became a wholly-owned subsidiary of GEEC.

The Company ceased business operation in mid- to late-2016. All subsidiaries, except for GESPL, were closed or disposed before end of 2016.is currently a shell company.

Since its inception, the Company has always been in the development stage and never generated significant revenues. The Company is planning to engage in the business of distribution and sales of medical test kits and personal protection equipment (“PPE”) in the United States. The Company’s activities are subject to significant risks and uncertainties, including failing to secure additional funding to operationalizeoperate the Company’s current objectiveproposed medical test kits and PPE business. 

On December 15, 2020, the Company made the First Tranche Investment in Hukui, by purchasing 80,000 shares of commencing the nasal spray business. Hukui’s Series C Preferred Stock for $800,000.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S.US GAAP”). The accompanying unaudited condensed consolidated financial statements reflect all adjustments, consisting of only normal recurring items, which, in the opinion of management, are necessary for a fair statement of the results of operations for the periods shown and are not necessarily indicative of the results to be expected for the full year ending September 30, 2020.2021. These unaudited condensed consolidated financial statements should be read in conjunction with the condensed consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the year ended September 30, 2019.2020.

Principle of Consolidation

The condensed consolidated financial statements include the accounts of GEEC and its wholly-owned subsidiary GESPL. All significant inter-company accounts and transactions have been eliminated in consolidation. The other wholly-owned subsidiary of the Company did not have business or accounting activities during the six-month periodssix months ended March 31, 20202021 and 2019.2020.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. For the six-month periodssix months ended March 31, 20202021 and 2019,2020, no significant estimates and assumptions have been made in the condensed interim consolidated financial statements.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consisted primarily of cash, to the extent balances exceeded limits that were insured by the Federal Deposit Insurance Corporation. The Company does not require collateral and maintains reserves for potential credit losses. Such losses have historically been immaterial and have been within management’s expectations.

Cash and Cash Equivalents

The Company considers all highly liquid instruments with original maturities of three months or less when acquired to be cash equivalents. As of March 31, 20202021 and September 30, 2019,2020, the Company did not have cash equivalents. The Company’s cash was denominated in United States Dollars (“US$”USD”) or New Taiwan Dollars (“TWD”) and was placed with banks in the United States of America and Taiwan.

Fair Value of Financial Instruments

The Company follows the guidance of the ASC Topic 820-10, “Fair Value Measurements and Disclosures” (“ASC 820-10”), with respect to financial assets and liabilities that are measured at fair value. ASC 820-10 establishes a three-tier fair value hierarchy that prioritizes the inputs used in measuring fair value as follows:

The Company’s financial instruments consist principally of cash and cash equivalents, accounts payable and accrued expenses, and due to related parties.parties, and notes payable. The carrying amounts of such financial instruments in the accompanying condensed consolidated balance sheets approximate their fair values due to their relatively short-term nature. It is management’s opinion that the Company is not exposed to any significant currency or credit risks arising from these financial instruments.

Foreign Currency Translation and Transactions

The reporting and functional currency of GEEC is the US$.USD. The functional currency of GESPL, a wholly owned subsidiary of GEEC, is the SGD.Singapore Dollar (“SGD”).

For financial reporting purposes, the financial statements of the Company’s Singapore subsidiary, which are prepared using the SGD, are translated into the Company’s reporting currency, US$.USD. Assets and liabilities are translated using the exchange rate on the balance sheet date, which was 0.70340.7437 and 0.72360.7325 as of March 31, 20202021 and September 30, 2019,2020, respectively. Revenue and expenses are translated using average exchange rates prevailing during each reporting period. The 0.72780.7468 and 0.73250.7278 average exchange rates were used to translate revenues and expenses for the six-month periodssix months ended March 31, 20202021 and 2019,2020, respectively. Stockholders’ equity (deficiency) is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive income (loss) in stockholders’ equity (deficiency).

Transactions denominated in currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates of the transactions. The resulting exchange difference, presented as foreign currency transaction gain (loss),loss, is included in the accompanying condensed consolidated statements of operations.

Business Segments

The Company operates in only one segment.

Net Income (Loss) Per Share

The Company calculates net income (loss)loss per share in accordance with ASC Topic 260, “Earnings per Share.” Basic income (loss)loss per share is computed by dividing the net incomeloss by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed similar to basic incomeloss per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common stock equivalents had been issued and if the additional common shares were dilutive. There were no potential dilutive debt or equity instruments issued and outstanding at any time during the six-month periodssix months ended March 31, 20202021 and 2019.2020.

Discounts on Common Stock

Common stocksstock issued underlower than the Company’s par value areis treated as common stocksstock issued under discounts. The portion of the discount is shown separately as a deduction from the Company’s account of common stock on the Company’s condensed consolidated financial statements.

Stock-Based Compensation

The Company accounts for its stock-based compensation in which the Company obtains employee services in share-based payment transactions under FASB ASC Topic 718, Compensation – Stock Compensation, which requires the Company to expense the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of such instruments over the vesting period.

The Company also adopted FASB ASC Topic 505-50, Equity-Based Payments to Non-Employees, to account for equity instruments issued to parties other than employees for acquiring goods or services. Such awards for services are recorded at either the fair value of the consideration received or the fair value of the instruments issued in exchange for such services, whichever is more reliably measurable.

No stock based compensation was issued or outstanding during the six-month periods endedEffective March, 31, 20202021, the Company issued shares to repay accrued and 2019.unpaid compensation to the Company’s Chief Executive Officer, Chief Financial Officer, certain employees and a consultant. See note 7.

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded to reduce the Company’s deferred tax assets to the amount that is more likely than not to be realized. 

The Company considers positive and negative evidence when determining whether a portion or all of its deferred tax assets will more likely than not be realized. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carry-forward periods, its experience with tax attributes expiring unused, and its tax planning strategies. The ultimate realization of deferred tax assets is dependent upon its ability to generate sufficient future taxable income within the carry-forward periods provided for in the tax law and during the periods in which the temporary differences become deductible. When assessing the realization of deferred tax assets, the Company has considered possible sources of taxable income including (i) future reversals of existing taxable temporary differences, (ii) future taxable income exclusive of reversing temporary differences and carry-forwards, (iii) future taxable income arising from implementing tax planning strategies, and (iv) specific known trend of profits expected to be reflected within the industry.

The Company recognizes a tax benefit associated with an uncertain tax position when, in its judgment, it is more likely than not that the position will be sustained upon examination by a taxing authority. For a tax position that meets the more-likely-than-not recognition threshold, the Company initially and subsequently measures the tax benefit as the largest amount that the Company judges to have a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority. The Company’s liability associated with unrecognized tax benefits is adjusted periodically due to changing circumstances, such as the progress of tax audits, case law developments and new or emerging legislation. Such adjustments are recognized entirely in the period in which they are identified. The Company’s effective tax rate includes the net impact of changes in the liability for unrecognized tax benefits and subsequent adjustments as considered appropriate by management. The Company classifies interest and penalties recognized on the liability for unrecognized tax benefits as income tax expense.

There were no current and deferred income tax provision recorded for the six-month periodssix months ended March 31, 20202021 and 20192020 since the Company is in developing stage and did not generate any revenues in the two fiscal periods.

Recent Accounting Pronouncements

The Company has reviewed the following recent accounting pronouncements and concluded that they were either not applicable or had no impact to the Company’s condensed consolidated financial statements:

In May 2014,August 2020, the FASB issued ASU 2014-09, Revenue from Accounting Standards Update No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts with Customers (Topic 606), ASU 606, to clarify the principles of recognizing revenue and create common revenue recognition guidance between U.S. GAAP and International Financial Reporting Standards (“IFRS”)in Entity’s Own Equity (Subtopic 815-40). The new guidance establishessubtitle is Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This Accounting Standard Update (“ASU”) addresses complex financial instruments that have characteristics of both debt and equity. The application of this ASU would reduce the principlesnumber of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models would result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to report useful informationbe subject to users of financial statements about the nature, timing,separation models are (1) those with embedded conversion features that are not clearly and uncertainty of revenue from contracts with customers. An entity has the option to apply the provisions of ASU 2014-09 either retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this standard recognized at the date of initial application. ASU 2014-09 is effective for public business entities for fiscal years and interim periods within those years beginning after December 15, 2017, and early adoption is permitted but not earlier than the original effective date of December 15, 2016. For all other entities, ASU 606 is effective for annual reporting periods beginning after December 15, 2018, and interim reporting periods within annual reporting periods beginning after December 15, 2019. The new standard currently is not applicableclosely related to the Company sincehost contract, that meet the Company is still in development stagedefinition of a derivative, and doesthat do not generate revenue.

In January 2016, the FASB issued ASU 2016-01, Financial Instruments–Overall: Recognition and Measurement of Financial Assets and Financial Liabilities. The new guidance will impact the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the FASB clarified the needqualify for a valuation allowance on deferred tax assets resultingscope exception from unrealized losses on available-for-salederivative accounting and (2) convertible debt securities. The accountinginstruments issued with substantial premiums for other financial instruments,which the premiums are recorded as paid-in capital. To date, no such as loans, investments in debt securities, and financial liabilities not underbifurcation has been necessary. Management is evaluating the fair value option is largely unchanged. The standard is effective for public business entities for annual periods (and interim periods within those annual periods) beginning after December 15, 2017. For all other entities, it ispotential impact. This ASU becomes effective for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning after December 15, 2019. The new guidance does not have impact to the Company’s condensed consolidated financial statements for the six-month periods ended March 31, 2020 and 2019 since the Company does not have equity investments and financial liabilities measured under the fair value option.2023.

In February 2016, FASB issued ASU No. 2016–02, “Leases (Topic 842)”, ASC 842, and subsequently amended the guidance relating largely to transition considerations under the standard in July 2018. The new guidance, which creates new accounting and reporting guidelines for leasing arrangements, requires organizations that lease assets to recognize assets and liabilities on the balance sheet related to the rights and obligations created by those leases, regardless of whether they are classified as finance or operating leases. Consistent with current guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease primarily will depend on its classification as a finance or operating lease. The guidance also requires new disclosures to help financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. The new standard is effective for public business entities for annual reporting periods beginning after December 15, 2018, including interim periods within that reporting period, with early application permitted. In March 2019,2020, the FASB issued ASU 2019-01, Leases (Topic 842)Accounting Standards Update No. 2020-03, Codification Improvements which further clarifiesto Financial Instruments. There are seven issues addressed in this update. Issues 1 through 5 were clarifications and codifications of previous updates. Issue 3 relates only to depository and lending institutions and therefore would not be applicable to the determinationCompany. Issue 6 was a clarification on determining the contractual term of fair valuea net investment in a lease for purposes of measuring expected credit losses, an issue not applicable to the underlying asset by lessors that are not manufacturers or dealers and modifies transition disclosure requirements for changes in accounting principles and other technical updates. The amendments in ASU 2019-01 amend Topic 842Company. Issue 7 relates to the regaining control of financial assets sold and the effective daterecordation of those amendments isan allowance for fiscal years beginning December 15, 2019, and interim periods within those fiscal years for public business entities. For all other entities, ASC 842 is effective for annual periods beginning after December 15, 2020.credit losses. The Company is currently evaluating the impact of the new pronouncement on its condensed consolidated financial statements but does not expect it to have a significant impact.

In June 2016, the FASB amended guidanceamendment related to impairment of financial instruments as part of ASU 2016-13 Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which will beissues 1, 2, 4 and 5 become effective January 1, 2020. The guidance replaces the incurred loss impairment methodology with an expected credit loss model for which a Group recognizes an allowance based on the estimate of expected credit loss. The Company does not expect that theimmediately upon adoption of the standard to have an impact on the Company’s condensed consolidated financial statements.

In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments”. ASU 2016-15 provides guidance for eight specific cash flow issues with respect to how cash receipts and cash payments are classified in the statements of cash flows, with the objective of reducing diversity in practice. The effective date for ASU 2016-15 is for annual periods beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. For all other entities, the amendments areupdate. Issue 3 becomes effective for fiscal years beginning after December 15, 2018,2019. Issues 6 and interim periods within fiscal years beginning after December 15, 2019. The7 become effective on varying dates that relate to the dates of adoption other updates. Management’s initial analysis is that it does not believe the new guidance does not havewill substantially impact to the Company’s condensed consolidated financial statements for the six-month periods ended March 31, 2020 and 2019 since the Company had limited cash flow activities and its cash flow activities were not within the scope of the eight specific cash flow issues under the ASU 2016-15 guidance.

In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230) (“ASU 2016-18”). This ASU affects all entities that have restricted cash or restricted cash equivalents and are required to present a statement of cash flows under Topic 230. ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. This update will become effective for fiscal years beginning after December 15, 2018, and interim periods within fiscal years beginning after December 15, 2019, and early adoption is permitted in any interim or annual period. The adoption of the guidance does not have impact to the Company’s statement of cash flows as the Company currently does not have restricted cash or restricted cash equivalents.

In June 2018, the FASB issued ASU 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, The ASU provides final guidance aligning the measurement and classification guidance for share-based payments to nonemployees with the guidance for share-based payments to employees, with certain exceptions. Under the guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date, which may lower their cost and reduce volatility in the income statement. The guidance allows nonpublic entities to account for nonemployee awards using certain practical expedients that are already available for employee awards, but the same accounting policies must be used for awards to both employees and nonemployees. The guidance is effective for public business entities in annual periods beginning after December 15, 2018, and interim periods within those years. For all other entities, it is effective in annual periods beginning after December 15, 2019, and interim periods within annual periods beginning after December 15, 2020. Early adoption is permitted, including in an interim period, but not before an entity adopts the new revenue guidance. The new guidance should be applied to all new awards granted after the date of adoption. In addition, all liability-classified awards that have not been settled and equity-classified awards for which a measurement date has not been established under ASC 505-50 by the adoption date should be re-measured. These awards should be re-measured at fair value as of the adoption date, with a cumulative effect adjustment to opening retained earnings in the fiscal year of adoption. The Company is still in the process of evaluation of the impact but does not expect the adoption of the guidance to have an impact to the Company’s condensed consolidated financial statements since the Company currently does not have share-based payments to non-employees.statements.

In August 2018, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) ASU 2018-13, - Fair“Fair Value Measurement (Topic 820) Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement.Measurement”. The amendments in this update apply to all entities that are required, under existing GAAP, to make disclosures about recurring or nonrecurring fair value measurements. The amendments in this update modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. The amendments in this update are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company will evaluate the impact of the new standards in the fiscal year when it becomes effective.

NOTE 3 – GOING CONCERN

As of March 31, 20202021 and September 30, 2019,2020, the Company had an accumulated deficit of $8,002,179$8,323,317 and $7,847,280,$8,158,389, respectively. To date, the Company’s cash flow requirements have been primarily met through proceeds received from sales of common stock.Common Stock. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets and liabilities that may result in the Company not being able to continue as a going concern.

The Company is actively pursuingintends to pursue additional funding, subject to the requirement that the Company increase the number of authorized and unissued shares of its Common Stock before engaging in further capital raising transactions and strategic partnersfinancing to enable it to implement the Company’s business plan. Management believes that these actions, if successful, will allow the Company to continue its operations through the next 12 months. However, there are no commitments in place for such financing currently.

NOTE 4 – INVESTMENT

On December 15, 2020, the Company purchased 80,000 shares of Series C Preferred Stock (“Series C Preferred Shares”), at $10.00 per share, for a total purchase price of $800,000, from Hukui Biotechnology Corporation (“Hukui”), pursuant to that certain Series C Preferred Shares Subscription Agreement dated September 23, 2020 (the “Hukui Agreement”). As previously reported, pursuant to the Hukui Agreement, the Company has agreed to purchase an aggregate 200,000 Series C Preferred Shares, at $10.00 per share, for an aggregate investment of $2,000,000, in a series of three closings from December 15, 2020 through June 30, 2022. Total investment consists of less than 20% of Hukui’s total equity with no significant control over Hukui. The investment is recorded at cost. The management quarterly reviews the investment for possible impairment. As of March 31, 2021 the Company believes that there is no impairment.

NOTE 5 – NOTES PAYABLE – RELATED PARTY

In April, May, July and August 2020, the Company’s President and Chief Executive Officer, Jui Pin Lin, made loans to the Company primarily to pay the Company’s expenses. The promissory notes the Company issued to evidence these loans are due as to both principal and simple interest in six months from their respective issuance dates.

NOTE 7 – STOCKHOLDERS’ EQUITY (DEFICIENCY)

The Company is authorized under its articles of incorporation, as amended, to issue 10,000,000,000 shares of Common Stock, par value $0.001 per share.

Issuance of Common Stock

During the six-month periodsyear ended March 31,September 30, 2020 the Company issued 3,834,000 shares of Common Stock to related parties to repay unpaid compensation and 9,000,000 shares of Common Stock to the CEO for stock previous not issued due to limited number of authorized shares. For the year ended September 30, 2019 the Company did not issue any common stock.

Disputed Sharesissued 4,091,720 shares of Common Stock for equity financing and 18,000,000 shares of Common Stock to the CEO for settlement.

Pursuant toOn December 15, 2020, the Natfresh Exchange Agreementon August 19, 2014, among the shares issued by GEEC to all Natfresh shareholders were 546,460,641Company completed a private offering of its Common Stock. The Company sold 107,000,000 shares of GEECits Common Stock constitutingto 34 individuals at a purchase price of $0.01 per share, for gross proceeds of $1,070,000, before allocating certain expenses associated with the Disputed Shares, which were issued by Oliver Lin’s management to Group B. The Company’s current management believes that the Disputed Shares should have been issued to Group A, since Group A, rather than Group B, had paid for the shares in questionoffering in the Natfresh Offering. However,amount of $5,852 as adjusted paid-in capital.

Effective March 31, 2021, the Company issued an aggregate 6,399,965 shares of its Common Stock to certain of its directors, officers, employees and a consultant, who converted accrued and unpaid compensation in the aggregate amount of $94,398. Of this amount, (i) $37,998 was with respect to amounts accrued during fiscal year 2020 and was converted at a rate of $0.05 per share into an aggregate 759,965 shares of its Common Stock; and (ii) $56,400 was with respect to amount accrued during fiscal year 2021 through March 31, 2021 and was converted at a rate of $0.01 per share into an aggregate 5,640,000 shares of its Common Stock.

Certain Effects of the Reverse Stock Split

On June 23, 2020, the Company’s current management believes also that all sharesBoard of Natfresh commonDirectors approved a reverse stock including the Disputed Shares, were fully paid at the timesplit of the Natfresh Offering and, therefore, all such shares, includingCompany’s Common Stock, at a ratio of 1-for-100 (the “Reverse Stock Split”). The Reverse Stock Split became effective with the Disputed Shares, that were issued pursuant to the Natfresh Exchange Agreement were fully paid at the timeSecretary of their issuance.

The Company’s management has been informed that Group A and Group B have entered into an agreement (the “Group A/Group B Settlement Agreement”) pursuant to which, among other things, (i) Group B transferred allState of the Disputed Shares to Group AState of Nevada at 9:00 a.m. on July 6, 2020 (the “Effective Date”), and on July 23, 2020 with the Financial Industry Regulatory Authority and in proportion to the consideration paid by the individuals comprising Group A during the Natfresh Offering and (ii) both Group A and Group B have indemnified the Company and agreed to hold the Company harmless for all matters arising out of or related in any manner whatsoever to the Disputed Shares.marketplace.

The Group A/Group B Settlement Agreement has been executed and the transferaggregate par value of the Disputed Sharesoutstanding Common Stock was completed on December 16, 2019. Because Taiwan,reduced, while the jurisdictionaggregate capital in whichexcess of par value attributable to the outstanding Common Stock for statutory and accounting purposes was correspondingly increased. The Reverse Stock Split will not affect the Company’s total stockholders’ equity. All share and per share information will be retroactively adjusted following the Effective Date to reflect the Reverse Stock Split for all Group B members reside, does not have a medallion or other third-party signature guarantee system, uponperiods presented in future filings. 

On the requestEffective Date, the total number of shares of the Company’s transfer agent,Common Stock held by each shareholder were converted automatically into the number of whole shares of Common Stock equal to (i) the number of issued and outstanding shares of Common Stock held by such shareholder immediately prior to the Reverse Stock Split, divided by (ii) 100.

No fractional shares were issued in connection with the Reverse Stock Split, and no cash or other consideration was be paid. Instead, the Company has agreedissued one whole share of the post-Reverse Stock Split Common Stock to indemnify and assume all liabilityany shareholder who otherwise would have received a fractional share as a result of the Reverse Stock Split. The Company is currently authorized to issue 10,000,000,000 shares of Common Stock. As a result of the Reverse Stock Split, the total number of authorized shares did not change.

The Reverse Stock Split did not have any effect on the stated par value of the Company’s transfer agentCommon Stock. The rights and its agentsprivileges of the holders of shares of Common Stock will be unaffected by the Reverse Stock Split. All options, warrants and employees, from any dispute, loss, damageconvertible securities of the Company outstanding immediately prior to the Reverse Stock Split will be appropriately adjusted by dividing the number of shares of Common Stock into which the options, warrants and convertible securities are exercisable or expense which may arise directlyconvertible by 100 and multiplying the exercise or indirectlyconversion price thereof by reason thereof.100.

NOTE 58 – RELATED PARTY TRANSACTIONS

Related Parties

Due to related party balance

The Company’s related party balances are as follows:

The balances due to AMCM were carried forward from previous year and related to sharing of office space in Singapore. The balances due to AMCM changechanged from $62,883$63,656 at September 30, 2020 to $61,127 mainly$64,632 at March 31, 2021, primarily due to the changes in foreign currency translation. We believe that AMCM is controlled by Yi Lung (Oliver) Lin.

The balances due to James Tsai, Betty ChenJui Pin (John) Lin, and James HsuShao-Cheng (Will) Wang were related to unpaid compensationscompensation due to these current and former officers and directors. Increase indirector. The balances due to James Tsai, Betty Chen and James Hsu were compensations for the six-month periods endedhave been paid off as of March 31, 2020.2021, see note 7.

The related party balances are unsecured, interest-free and due on demand.

NOTE 69 – STOCK-BASED COMPENSATION

On May 6, 2019, theThe Company’s Board of Directors passed a resolution to allowhas previously authorized unpaid officer salaries and car allowancedirector fees to be settled, throughat the option of the individual, by conversion toof such amounts into shares of the Company’s common stockCommon Stock at a price of $0.0005$0.05 per share. $18,000As a result, $27,000, $12,000, and $12,000 are expected to$4,200 may be converted into 36,000,000540,000, 240,000, and 24,000,00084,000 shares, respectively, as officers’ compensation for services performed for the six-month periodyear ended September 30, 2020 by Kuang Ming Tsai, Yi Ling Chen and Ching Ming Hsu, respectively.

Effective March 31, 2021, the Company issued an aggregate 6,399,965 shares of its Common Stock to certain of its directors, officers, employees and a consultant, who converted accrued and unpaid compensation in the aggregate amount of $94,398. Of this amount, (i) $37,998 was with respect to amounts accrued during fiscal year 2020 and was converted at a rate of $0.05 per share into an aggregate 759,965 shares of its Common Stock; and (ii) $56,400 was with respect to James Tsai Kuan Ming and Betty Chen Yi Ling, respectively. $4,200 is expected to be settledamount accrued during fiscal year 2021 through conversion into 8,400,000 shares for director’s fee by James Hsu Chin Ming during the six-month period ended March 31, 2020. However, these conversions cannot take place2021 and the related shares issued until such time as the Company shall havewas converted at a sufficient numberrate of authorized and unissued$0.01 per share into an aggregate 5,640,000 shares of its Common Stock available for such issuance. Stock.

The expenses have been reflected in the accompanying condensed consolidated financial statements.

NOTE 710 – INCOME TAXES

The Company has not generated any revenue from any source in the United States and had consolidated net loss for all the years since inception in 2010. Management believes GEEC does not have any U.S. income tax liability due. However, even the Company does not have U.S. income tax liability, it may be required to file Form 5471 each year with the Internal Revenue Service (the “IRS”) of Department of Treasury. GEEC falls in the Category Five Filer (as a domestic corporation). The Company used to have subsidiaries: GEECIS in Sri Lanka that was established in May 2011, GESPL in Singapore that was established in February 2012, and GESTL in Thailand that was established in December 2014. The subsidiaries in Sri Lanka and Thailand were disposed in 2014 and 2016, respectively, and the Singapore subsidiary has been inactive since 2016.

Internal Revenue Code (“IRC”) Section 6038(a) requires information reporting with respect to certain foreign corporations (Form 5471) and describes the information required to be reported on this form. IRC Section 6038(b)(1) provides for a monetary penalty of $10,000 for each Form 5471 that is filed after the due date of the income tax return (including extensions) or does not include the complete and accurate information described in Section 6038(a). According to IRS rules, a penalty may apply to each Form 5471 which is filed after the due date of the income tax return. The penalty will be applied whether or not any tax is due on Form 1120.

The Company believes that based on the current information available, it is difficult to determine whether it is probable that the Company will be charged penalties by IRS for the late filing of Form 5471 and even if it will be, it is difficult to reasonably estimate the amount of penalties that may be assessed. On November 30, 2019, the Company filed Form 1120 for the fiscal years ended September 30, 2014 through September 30, 2018.

NOTE 811 – COMMITMENTS AND CONTIGINCIES

Operating lease commitments

The Company has aterminated its virtual office agreement in Los Angeles.Angeles, California and has established a new virtual office in Arcadia, California. The Agreementnew arrangement is on a month-to-month basis. One month’s written notification is required by either party to terminate this Agreement.basis at a cost of $200 per month. As of March 31, 2020,2021, the Company has no material commitments under operating leases.

NOTE 912 – SUBSEQUENT EVENTS

On April 24, 2020, the Company’s President and Chief Executive Officer, Jui Pin Lin, loaned9, 2021, the Company repaid the October 2020 Loan from a stockholder for the unpaid principal amountand interest accrued until the Maturity Date in the form of $25,000 (the “Loan”), primarily to pay certain expenses. The Loan bears simple interesta conversion at a rate of 1%$0.01 per annum, and is payable as to both principal and interest on October 24, 2020 (the “Maturity Date”).

Mr. Lin, as the holder of the promissory note (the “Note”) evidencing the Loan, may, at his sole option, convert (a “Voluntary Conversion”) the outstanding principal and accrued and unpaid interested on the Noteshare into 3,059,836 shares of the common stock of the Company (“Company’s Common Stock”) at a rate of $0.0005 per share. Notwithstanding the holder’s right of Voluntary Conversion, the holder of the Note may not make such conversion unless and until the Company has a sufficient number of authorized and unissued shares of Common Stock to issue upon a Voluntary Conversion. At the present time, the Company does not have a sufficient number of authorized and unissued shares of its Common Stock to issue upon a Voluntary Conversion but expects to have a sufficient number of authorized and unissued shares of its Common Stock before the Maturity Date.Stock.

GENERAL NOTE

ThroughoutA 1-for-100 reverse stock split (the “Reverse Stock Split”) of our common stock (the “Common Stock”) became effective with the State of Nevada on July 6, 2020 and with the Financial Industry Regulatory Authority and in the market on July 23, 2020 (the “Effective Date”). Unless expressly stated herein, all share amounts of our Common Stock presented in this report we referhave been adjusted to our business fromreflect the period from inception (June 21, 2010) through approximately mid- to late-2016, as our “historic period”, the business conducted during the historic period as our “original business” and the management of our company during the historic period as “previous management” or “Oliver Lin’s management”.Reverse Stock Split.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This document contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws, including, but not limited to, any projections of earnings, revenue or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing.

Forward-looking statements may include the words “may,” “could,” “will,” “estimate,” “intend,” “continue,” “believe,” “expect”, “anticipate”, “hope” or other similar words. These forward-looking statements present our estimates and assumptions only as of the date of this report. Except for our ongoing obligation to disclose material information as required by the federal securities laws, we do not intend, and undertake no obligation, to update any forward-looking statement.

Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and inherent risks and uncertainties. Some of the key factors impacting these risks and uncertainties include, but are not limited to:

Overview

DuringIn 2019 and through early 2020, we had planned to restart our historic period, we were a start-up company whose main focus was to promote, market, distribute and export a range oforiginal enzyme products for human and animal consumption, manufactured inbusiness, by importing enzyme supplements from the United States for sale in certain Asian markets, including Taiwan and other nations in the Association of Southeast Asian Nations (“ASEAN”). Our objective was to commence marketing and distribution of American range of enzyme products for human and animal consumption to sole country distributors, wholesalers, dealers and retailers, as well asTaiwan. However, due to the general public following a Multi-Level Marketing – Franchise Investor Dealer Related (MLM-FIDR) concept, to begin with, in Taiwan, and then to China, Hong Kong, Macau, Thailand, Malaysia, Singapore and Sri Lanka.

During our historic period, we were in the development stage with no significant revenues.  The Company’s initial operations included organization, capital formation, target markets identification and developing marketing plans. At some point, which we believe may have commenced beginning approximately mid- to late-2016, previous management ceased operating our original business. We have not had any revenues from operations since that time. 

Highlights

As previously reported, in April 2020 management of our company changed. For the reasons stated in this report, our new management has decided not to restart our enzyme products business. Management’s new plan of operations is set forth below. Notwithstanding the foregoing, management and the Board of Directors may amend or abandon at any time our new plan of operations, which itself in its earliest phase.

Plan of Operations

The following plan of operations is tentative and subject to change. Preliminarily, we estimate that we will need approximately $1,000,000 to fund our new plan of operations over the next 12 months,COVID-19 pandemic, all non-COVID-19 related matters, including without limitation permit applications with the national Food and Drug Administration (“FDA”) in each country where we intend to sell our product, manufacturing costs, marketing expenses and advertising costs. We do not have such funds available and there is no commitment to fund such amount, or any amount, that we need to meet our expenses and pursue our new plan of operations.

As previously reported, we had planned to establish a branch in Taiwan to import enzyme supplements from the United States. The process of applying for supplementobtaining an import license from Taiwan’s Ministry of Economic Affairs and FDA usually takes approximately over one year. Due to the COVID-19 pandemic, all non COVID-19 related matters have beenTaiwan Food and Drug Administration (“FDA”), were delayed or arewere taking longer than usual in Taiwan since late Januarybeginning in late-January 2020. For various reasons, including the fact that, without a reasonably foreseeable end of the pandemic and Taiwan government resources being shifted to dealing with the pandemic, our managementwe decided to abandon the plan to restart our enzyme products business.

Nasal Spray Product

Management isIn May 2020, we announced that we were in the preliminary stage of developing a new business plan to sell and distribute Physiological Sea Waterphysiological sea water and Nasal Spraynasal spray in Taiwan and the United States. The spray isHowever, after exploring this possible business as a compositionresult of isotonic PH of crystals of sea water dilutedseveral factors, including but not limited to difficulties in purified water and aerosol cans. The product is market ready and similar products are currently being soldcommencing a new business during the ongoing COVID-19 pandemic, in China.

Saline nasal sprays can be used to moisturize dry sinus cavities and help remove debris or pollens from the nose. The spray is comprised of water and salt or sodium. It is less expensive than other options and be easily applied at home. We believeSeptember 2020 we announced that Physiological Sea Water Nasal Spray may provide certain relief from common nasal congestion, flush out irritants, and moisturize dry nasal passages related to allergies, colds, flu and sinusitis. However, the product is not a medical treatment for any health condition or illness, including without limitation allergies, colds, flu and sinusitis, andwe will not be labeled as having a therapeutic purpose.

Manufacturing

We currently do not have our own production plant to makepursue the product. We intend to outsource the production of the product to third party manufacturers, using our label for branding purposes.nasal spray business.

We have identified a manufacturer in Shanghai, China to produceare currently exploring business opportunities for products with high demand since the product for us. Because manufactureadvent of the productCOVID-19 pandemic in the areas of medical test kits and personal protection equipment (“PPE”). We are exploring marketing two COVID-19 rapid test kits which will be useful during the pandemic period, as well as a medical mask, medical-grade gloves and possibly other PPE.

In late September 2020, we announced that Hukui and we had entered into a Series C Preferred Shares Subscription Agreement dated September 23, 2020 (the “Hukui Agreement”), pursuant to which we have agreed to purchase an aggregate 200,000 shares of Hukui’s Series C Preferred Stock (“Series C Preferred Shares”) at $10.00 per share, for an aggregate investment of $2,000,000. 

We will purchase the Series C Preferred Shares in three tranches, through a date on or before June 30, 2022, as follows:

If Hukui does not involve complex processes,achieve further milestones or meet further conditions, we believewill have the option either to (i) abandon the Second Tranche Investment and/or the Third Tranche Investment, or (ii) waive the failure of Hukui to meet such conditions and proceed with the Second Tranche Investment and/or the Third Tranche Investment.

Notwithstanding the foregoing, management and the Board of Directors may amend or abandon at any time our current intended investment in Hukui and/or develop a business plan for a new business that we would operate and/or engage in a reverse merger with another company. 

If we do not actively pursue and implement our current plan of operations to operate a business or engage in a reverse merger with another company, we may be obligated to register and operate as an investment company under the Investment Company Act of 1940 as a result of our investment in Hukui.

Regardless of which overall business strategy we pursue – starting our own operating business, engaging in a reverse merger or being an investment company – we will continue to need capital to meet our expenses, primarily overhead and the professional fees related to the cost of compliance as a reporting company. We must also raise funds to meet our obligation to invest $0.6 million in Hukui in the Second Tranche Investment on or before June 30, 2021. There are no commitments in place to fund any such business or fund the Second Tranche Investment and no guarantee can be given that we will be able to find additionalsecure such funding on terms that are favorable to us, or at all.

For the fiscal year ended September 30, 2020, Jui Pin (John) Lin, our President and Chief Executive Officer, provided such capital periodically in the form of loans in the aggregate principal amount of $120,410. On December 28, 2020, we repaid Mr. Lin $65,410 of the principal amount of loans due and payable plus accrued interest in the amount of $1,162, for a total of $66,572. On January 5, 2021, we repaid Mr. Lin $20,000 of the principal amount of another such loan due and payable plus accrued interest in the amount of $403, for a total of $20,403. All amounts owed by us to Mr. Lin were repaid as of March 31, 2021.

In the six months ended March 31, 2021, another stockholder loaned us $30,000. The loan matured on April 9, 2021. The principal amount of the loan, together with accrued and unpaid interest, was convertible, at the option of the lender, into shares of our Common Stock at a rate of $0.01 per share. On April 9, 2021, the lender converted the $30,000 principal amount of this loan, together with accrued and unpaid in the amount of $858, into 3,085,809 shares of our Common Stock.

We may also raise equity, debt, convertible debt or a combination of any of the foregoing, from other parties for the capital we may need for any of the purposes specified in this report. There is no agreement in place between the Company and Mr. Lin, the other shareholder or anyone else, for such capital to continue to be made available to us as needed, and we cannot guarantee that any such capital will continue to be available to us on favorable terms, or at all, in the future.

Plan of Operations

The following plan of operations is tentative and subject to change, including but not limited to delays we are facing, and expect to continue to face, dealing with governmental agencies and other regulators as a result of reduced operations resulting from the COVID-19 pandemic. Management and the Board of Directors may amend or abandon at any time our new plan of operations, which itself in an early phase.

We are currently exploring business opportunities for products with high demand since the advent of the COVID-19 pandemic in the areas of medical test kits and PPE. We are exploring marketing two COVID-19 rapid test kits which will be useful during the pandemic period, as well as a medical mask, medical-grade gloves and possibly other PPE. The primary marketing period for the rapid test kits would be during the pandemic itself, while the medical mask, medical-grade gloves and other PPE may still be in demand after the pandemic but with lesser demand. The rapid test method and kits are similar to those already on the market. The manufacturers ifare working on regulatory review and when necessaryapproval to be accepted by the market and potential clients. We plan to initiate the business plan of the distribution and sale of the medical test kits and PPE discussed below within the next six months, subject to adequate funding, regulatory approval and other factors, some of which are beyond our control.

We may require up to approximately $2.2 million to commence the medical test kit and PPE business. We do not have the funds available to commence the medical test kits and PPE business and will have to raise capital in order to do so. There are no commitments in place for such capital and no assurance can be given that we can raise such capital on terms that are favorable to us, or ifat all.

Medical Test Kits

2019-nCoV IgG/IgM Antibody Rapid Test. The 2019-nCoV IgG/IgM Antibody Rapid Test is a rapid immuno-chromatographic assay for the identifiedsimultaneous detection of IgG and IgM antibodies to 2019-nCoV virus in human whole blood, serum or plasma. The assay is used as a screening test for 2019-nCoV viral infection and as an aid for differential diagnosis of acute phase infections or previous infections. We are currently communicating with one or more manufacturers in Taiwan for distribution of the rapid test in the United States. 

Vstrip COVID-19 Antigen Rapid Test. The Vstrip COVID-19 Antigen Rapid Test is a rapid in vitro immunochromatographic assay intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 in nasopharyngeal swab from individuals who are suspected of COVID-19 by their healthcare provider within the first five days of the onset of symptoms. We are currently communicating with one or more manufacturers in Taiwan for future distribution of the rapid test in the United States.

We do not have any agreement in place at this time with any manufacturer of either the antibody rapid test or the antigen rapid test.

PPE

3-Ply Medical Grade Mask. The medical-grade face mask is intended to be worn to protect against the spread or transmission of infectious germs during surgical interventions in operating theatres and other medical facilities. The main aim is to protect the patient against infectious germs. We are currently communicating with one or more manufacturers in Taiwan for future distribution of the masks in the United States. We do not have any agreement in place at this time with any manufacturer of the masks.

Nitrile Powder Free Examination Gloves. The nitrile powder-free medical grade gloves are intended to be used to prevent cross-contamination for general medical use. We have communicated with a manufacturer in Shanghai is not available. Because the ingredients containedMalaysia for proposed distribution of such gloves in the productUnited States.

Manufacturing

We do have our own manufacturing plants for the above mentioned products. We have contacted manufacturers with whom our management has previous relations. If we are not scarce,successful in our negotiations, we do not believewill purchase the test kits and/or masks, gloves and any other PPE directly from the manufacturers for sale in the United States.

We currently estimate that we will be subjectmay spend up to scarcityapproximately $1 million to purchase the products that we would sell in the United States, as part of raw materials or that these raw materials will be subjectthe total $2.2 million budget to inflationary pressures.

commence the medical test kits and PPE business.

Marketing

We plan to distribute the productPPE through online sales platform and distributors in Taiwanthe United States to sell our productthe products in retail stores. Subject toWe understand from the manufacturers that the mask and gloves have already received U.S. Food and Drug Administration (“FDA”) approval. We understand that the manufacturers of the rapid test kits have applied for, but not yet received, FDA approval in the United States, we also plan to market the product to wholesalers in the United States.approval. We will explore the market and sales channels duringbeginning in this pre-operational period. We are still developing a more detailed marketing timeline for the product.PPE.

We also intendcurrently estimate that we may spend up to establish wholesale distribution channels through distributors of health care products.  Another sales channel for us to pursue is through online retailing.  Our goal is for the product to be sold through wholesale channels to national chain stores as well as online sales platform. We plan to distribute the product to be soldapproximately $1.2 million on other stores and platforms. We currently do not plan to have the product sold through our website.

We expect to spend approximately $20,000 to $50,000 forvarious operational expenses, including marketing costs, which includesmay include sampling giveaway/testing, on-line marketing and printed marketing materials.materials, as part of the total $2.2 million budget to commence the medical test kits and PPE business.

Competition

The antigen and antibody rapid test kits are relatively new in the market. With vaccines being rolled out worldwide, we believe the demand for test kits will increase, since many businesses, including airlines, and many places, including tourist destinations, will require negative COVID tests, not just proof of vaccination, for the foreseeable future. Nonetheless, we will face significant competition from other manufacturers of rapid antigen and antibody tests, including Abbott Laboratories, Access Bio, Inc. and Babson Diagnostics, Inc., many of which companies have been in business longer than we have and have substantially larger resources than we have.

The nasal spray product,mask, gloves, and comparable products to the one we intend to manufacture and market,other possible PPE have an extremely low barrier to entry. Products similar to the product we intend to manufactureentry and markethave a highly fragmented market. Masks, gloves, and other PPE are currently being widely sold in the market under many different trade names. Therefore, we will face intense competition in the marketing of the productmasks with many companies, including Honeywell, 3M Company and Kimberley-Clark Corporation, a number of which have been in business much longer than we have and have substantially greater financial and other resources than we have.

Major competitors of gloves manufacturers includes Associated Bag, Caroline Glove Co., First Choice Industrial Supply Company, and various other companies, many of which have been in the business much longer than we have and have substantially greater financial and other resources than we have.

Regulation

The product will require certain regulatory compliance, including FDA approval, in each of the countries where we intendIn order to sell the product. The nature and extent of this compliance may vary based on the health and other claims we make. Management is preparing to file import permitsrapid test kits in Taiwan and the United State. We are currently in the earliest stage of seeking professional assistance in understanding the requirements and the application process for both Taiwan and the United States, FDA approval is required. We believe that the manufacturers to determine all necessary steps required with each country’swhom we are speaking have applied for FDA inapproval for their rapid test kits and are awaiting approval.

In order to properly disclosesell medical-grade masks and gloves, and possibly other PPE, in the ingredients, usageUnited States, FDA approval is required. We believe that the manufacturers to whom we are speaking have received FDA approval for their masks and other related disclosures regarding the product, to to obtain regulatory approval.

PPE.

Intellectual Property

WeAs distributors of other parties’ products, we do not believe that the ingredients contained in the nasal spray, the formulation of the nasal spray or the spray bottleswe have any protectable intellectual property meaning there are no patents we can file onfor the process of producing the product, the product itselftest kits, medical masks, or the container or delivery system of the product. However, we intend to register one or more trademarks under our name for branding purposes.

medical gloves.

Results of Operations

Three -MonthThree-Month Period Ended March 31, 20202021 compared to the Three-Month PeriodsPeriod Ended March 31, 20192020

Revenues

We did not generate any revenues during the three-month period ended March 31, 20202021 and March 31, 2019. Our former operating subsidiary, GESPL, ceased operation in 2016. 2020.

Operating Expenses

We incurred total operating expenses of $81,796$86,875 and $77,518$81,796 for the three-month periods ended March 31, 20202021 and 2019,2020, respectively. Our operating expenses consist of legal fees, other professional fees, payroll expenses, rent, and miscellaneous overhead, including bank charges, license and permits.transfer agent fees. The increase in operating expenses for the three-month period ended March 31, 20202021 compared to the three-monthssame period ended March 31, 2019in 2020 was mainlyprimarily due to an increase in our professionallegal fees and payroll expenses.

Net Loss

As a result of the above, our net loss increased from $77,526 in the three-month period ended March 31, 2019 to $81,795 in the three-month period ended March 31, 2020.

Six-Month Period Ended March 31, 2020 compared to the Six-Month Period Ended March 31, 2019

Revenues

We did not generate any revenues during the six-month periods ended March 31, 2020 and 2019. Our former operating subsidiary, GESPL, ceased operation in 2016. 

Operating Expenses

We incurred total operating expenses of $154,814 and $148,871 for the six-month periods ended March 31, 2020 and 2019, respectively. Our operating expenses consist of professional fees, payroll expenses, rent and miscellaneous overhead, including bank charges, license and permits. The increase in operating expenses for the six-month period ended March 31, 2020 compared to the six-month period ended March 31, 2019 was mainly due to an increase in our professional expenses.

Net Loss

As a result of the above, our net loss increased from $148,770$81,795 in the three-month period ended March 31, 2020 to $87,045 in the same period ended in 2021.

Six-Month Period Ended March 31, 2021 compared to the Six-Month Period Ended March 31, 2020

Revenues

We did not generate any revenues during the six-month period ended March 31, 20192021 and 2020.

Operating Expenses

We incurred total operating expenses of $163,575 and $154,814 for the six-month periods ended March 31, 2021 and 2020, respectively. Our operating expenses consist of legal fees, other professional fees, payroll expenses, rent, bank charges, and transfer agent fees. The increase in operating expenses for the six-month period ended March 31, 2021 compared to the same period ended in 2020 was primarily due to increase in legal fees and payroll expenses.

Net Loss

As a result of the above, our net loss increased from $154,899 in the six-month period ended March 31, 2020.2020 to $164,928 in the same period ended in 2021.

Effect of the COVID-19 Pandemic on our Business

While our liquidity and capital resources are severely limited and present serious obstacles to starting a business or continuing to meet or obligations to invest in Hukui, these limitations are unrelated to the COVID-19 pandemic and resulting global economic crisis.

We have been affected by the COVID-19 pandemic to the extent that it was one of a number of contributing factors in our decision to change our plan of operations from restarting our enzyme products business to selling the nasal spray product and then deciding not to pursue the nasal spray product business, although that decisionthe first of those two decisions was largely made prior to the full impact of the COVID-19 pandemic. Our personnel are in Taiwan, which has been relatively less affected by the pandemic compared to many other countries in Asia, Europe and the United States. While our liquidityNonetheless, we expect to experience delays in obtaining business licenses and capital resourcespermits, and any other governmental approvals that may be required for a future business, since government offices are severely limited and present serious obstaclescontinuing to our recommencing our enzyme products business, these limitations are unrelated towork with reduced staff during the pandemic and resulting global economic crisis.pandemic.

Nonetheless, depending upon the extent and duration of the pandemic and the resulting global economic crisis, these conditions may have an adverse impact on our ability to raise capital and commence our nasal spray product business.any business we may pursue. Depending upon possible changes in consumer demand, shopping and spending habits as a result of the pandemic and the resulting global economic crisis, we may also face challenges of consumer acceptance if and when we start to market our nasal spray product.

any products.

Liquidity and Capital Resources

Working Capital

As of March 31, 2021, we had current assets of $66,316 and a working capital deficit of $160,825. In comparison, as of September 30, 2020, we had cash and cash equivalents of $3,427$18,092 and a working capital deficit of $384,542. In comparison, as of September 30, 2019, we had cash and cash equivalents of $121,657 and a working capital deficit of $232,344.$352,943.

As of March 31, 2020,2021, we had total assets of $3,427,$866,316, compared with total assets of $121,707$18,092 at September 30, 2019.2020. The decreaseincrease in total assets was primarily due to decreaseincrease in cash and cash equivalents.equivalent from the private offering of our Common Stock and investment, which was completed in December of 2020.

We had $387,969$227,141 in total current liabilities as of March 31, 2020,2021, consisting of $127,793$130,722 in accounts payable, $243,827$1,787 in accrued expenses, $64,632 due to related parties, and $16,349$30,000 in accrued expenses.note payable. This is compared to total current liabilities of $354,051$371,035 as of September 30, 2019,2020, which included $128,971$129,154 in accounts payable, $211,383$25,436 in accrued expenses, $96,035 due to related parties and $13,697$120,410 in accrued expenses.notes payable – related party. The increase in due to related parties was primarily due to unpaid compensationscompensation to officers and directors.

We had a total stockholders’ deficiency of $384,542 and an accumulated deficit of $8,002,179 as ofDuring the six months ended March 31, 2020. In comparison, we had a total stockholders’ deficiency2021, one of $232,344 and an accumulated deficit of $7,847,280 as of September 30, 2019

On April 24, 2020, our President and Chief Executive Officer, Jui Pin Lin,shareholders loaned us the principal amount of $25,000$30,000 (the “Loan”“October 2020 Loan”), primarily to pay certainour expenses. The October 2020 Loan bears simple interest at a rate of 1%4% per annum and is payable as to both principal and interest on October 24, 2020 (the “Maturity Date”).

Mr. Lin, as the holderMaturity Date of April 9, 2021. On the promissory note (the “Note”) evidencingMaturity Date, the Loan, may, at his sole option, convert (a “Voluntary Conversion”)noteholder converted the outstanding principal, andtogether with accrued and unpaid interested on the Noteinterest into 3,059,836 shares of the common stock of the Company (“Company’s Common Stock”)Stock at a rate of $0.0005$0.01 per share. Notwithstanding

We had a total stockholders’ equity of $639,175 and an accumulated deficit of $8,323,317 as of March 31, 2021. In comparison, we had a total stockholders’ deficiency of $352,943 and an accumulated deficit of $8,158,389 as of September 30, 2020

On December 15, 2020, we completed a private offering of our Common Stock. We sold 107,000,000 shares of our Common Stock to 34 individuals at a purchase price of $0.01 per share, for gross proceeds of $1,070,000 before allocating certain expenses associated with the holder’s rightoffering in the amount of Voluntary Conversion,$5,852 as adjusted paid-in capital.

Effective March 31, 2021, we issued an aggregate 6,399,965 shares of our Common Stock to certain of our directors, officers, employees and independent consultants, who converted accrued and unpaid compensation in the holderaggregate amount of $94,398. Of this amount, (i) $37,998 was with respect to amounts accrued during fiscal year 2020 and was converted at a rate of $0.05 per share into an aggregate 759,965 shares of our Common Stock; and (ii) $56,400 was with respect to amount accrued during fiscal year 2021 through March 31, 2021 and was converted at a rate of $0.01 per share into an aggregate 5,640,000 shares of our Common Stock.

Reverse Stock Split

On June 23, 2020, our Board of Directors approved the Reverse Stock Split of our Common Stock, at a ratio of 1-for-100, as of the Note may not make such conversion unlessEffective Date. The Effective Date of the Reverse Stock Split with the Secretary of State of the State of Nevada was 9:00 a.m. on July 6, 2020 and untilJuly 23, 2020 with the Company has a sufficientFinancial Industry Regulatory Authority and in the marketplace.

On the Effective Date, the total number of authorized and unissuedshares of our Common Stock held by each shareholder was converted automatically into the number of whole shares of Common Stock equal to issue upon a Voluntary Conversion. At(i) the present time, the Company does not have a sufficient number of authorizedissued and unissuedoutstanding shares of itsCommon Stock held by such shareholder immediately prior to the Reverse Stock Split, divided by (ii) 100.

No fractional shares were issued in connection with the Reverse Stock Split, and no cash or other consideration was be paid. Instead, we issued one whole share of the post-Reverse Stock Split Common Stock to any shareholder who otherwise would have received a fractional share as a result of the Reverse Stock Split.

We are authorized to issue upon a Voluntary Conversion but expects to have a sufficient number of authorized and unissued10,000,000,000 shares of its Common Stock beforeand that number did not change as a result of the Maturity Date.Reverse Stock Split. 

The Note also provides for events of default and remedies in such event, including without limitation interest at a rate equal to the lesser of 10% per annum or the maximum interest rate allowed under usury or other similar laws from the Maturity Date until the Note is paid in full. The Note also contains other terms and conditions typical for a transaction of this type. There is no commitment from Mr. Lin, or anyone else, to continue to fund our expenses.

Cash Flows

During the six-month period ended March 31, 2021, we used $132,341 of cash in operating activities which was attributable primarily to our net loss of $164,928 offset by change in operating assets and liabilities of $32,587. In comparison, during the six-month period ended March 31, 2020, we used $118,230 of cash in operating activities which was attributable primarily to our net loss of $154,899 offset byand the change in operating assets and liabilities of $36,669. In comparison, during the six-month period ended March 31, 2019, we used $47,831 of cash in operating activities which was attributable to our net loss of $148,770 and the change in operating assets and liabilities of $100,939.

With respect to our investing activities, we had noused $800,000 in payment for investment made to Hukui during the six months ended March 31, 2021. We did not have investing cash activity in either period presented and we do not anticipate any significant capital expenditures inflow activities for the near future as such items are not required by us at this time.six months ended March 31, 2020.

With respect to our financing activities,During the six-month period ended March 31, 2021, we had nototal cash activityinflow of $973,738 from financing activities. We repaid $120,410 to notes payable–related party, which our President and Chief Executive Officer, Jui Pin Lin, previously loaned us. We received $30,000 from note payable as loan from a shareholder of the Company. We received $1,064,148, net of directly associated expenses, including legal, transfer agent, and printing and delivery expenses, from private offering of our Common Stock, which was completed in either period presented.December 2020. For accounting purpose, we recorded the net proceeds from private offering instead of the gross amount of $1,070,000.

There is substantial doubt that we can continue as an ongoing business for the next twelve months unless we obtain additional capital to pay our expenses as they become due. We do not anticipate any significant additional revenue until and unless we begin to execute on our plan of operations involving the restartstart of our enzyme productsnew nasal spray business. There is no assurance that we will ever reach that stage. The condensed consolidated financial statements presented herein do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be necessary in the event that we cannot continue as a going concern.

Our ability to continue as a going concern is dependent upon our ability to successfully execute our business plan and generate profitable operations in the future, and, until and unless we achieve that, to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operation as and when they become due. Management intends to finance operating costs for the foreseeable future with the issuance of equity and/or debt. While we have received certain loans from our President and Chief Executive Officer, Jui Pin (John) Lin, there is no standing commitment from Mr. Lin, or any person, for any such capital and there can be no assurances that capital will be available to us on favorable terms, or at all. Our failure to obtain adequate funding would be detrimental to us and result in the inability to execute our plan of operations, or even having to cease operations completely.

To date, our capital requirements have primarily been funded by shareholders through the purchase of our Common Stock in private offerings.offerings and short-term borrowings from our President and another shareholder. We currently estimate that we will need to raise additional capital of at least $200,000approximately $2,800,000, consisting of up to $300,000$2,200,000 to restartstart our enzyme productsnew medical test kits and PPE business over the next 12 months.nine months and $600,000 for the Second Tranche Investment in Hukui. We may also need to raise additional capital for corporate expenses. We are exploring options of raising additional capital through issuing more Common Stock or other securities, including debt and debt convertible into Common Stock, subject to the requirement that we must increase the number of authorized and unissued shares of our Common Stock, effect a reverse stock split or recapitalization transaction or series of transactions, before engaging in certain further capital raising transactions.  If and when appropriate, we will also consider raising capital from strategic alliance partners, which will not only provide needed additional capital but also potentially provide additional market access through deepening ties with our strategic partners.Stock. There are no agreements, arrangements or understandings in place with respect to raising any additional capital from any person. There can be no assurance that we will be able to raise such capital when and as needed on terms that are favorable to us, or at all.

Contractual Obligations

We do not have material contractual obligations and commitments. We only have one lease that is renewed on a month-to-month basis.

Off-Balance Sheet Arrangements

We have not entered into any other financial guarantees or other commitments to guarantee the payment obligations of any third parties. We have not entered into any derivative contracts that are indexed to our shares and classified as shareholder’s equity or that are not reflected in our condensed consolidated financial statements. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing, liquidity, market risk or credit support to us or engages in leasing, hedging or research and development services with us.

Critical accounting policies and estimates

Our discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. We continually evaluate our estimates, including those related to bad debts, inventories, recovery of long-lived assets, income taxes, and the valuation of equity transactions. We base our estimates on historical experience and on various other assumptions that we believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Any future changes to these estimates and assumptions could cause a material change to our reported amounts of revenues, expenses, assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions. For the three- and six-month periods ended March 31, 20202021 and 2019,2020, no significant estimates and assumptions have been made in the condensed consolidated financial statements. The following are some of the critical accounting policies in relation to the preparation of the condensed consolidated financial statements. For a full summary of our critical accounting policies, please refer to Note 2 of Notes to Condensed Consolidated Financial Statements.

Foreign currency translation

The financial statements of our subsidiary denominated in currencies other than the USD are translated into USD using the closing rate method. The balance sheet items are translated into USD using the exchange rates at the respective balance sheet dates. The capital and various reserves are translated at historical exchange rates prevailing at the time of the transactions while income and expenses items are translated at the average exchange rate for the period. All exchange differences are recorded in stockholders’ equity (deficiency).

Stock-Based Compensation

We account for stock-based compensation in which we obtain employee services in share-based payment transactions under FASB ASC Topic 718, Compensation – Stock Compensation, which requires us to expense the cost of employee services received in exchange for an award of equity instruments based on the grant date fair value of such instruments over the vesting period.

We also adopted FASB ASC Topic 505-50, Equity-Based Payments to Non-Employees, to account for equity instruments issued to parties other than employees for acquiring goods or services. Such awards for services are recorded at either the fair value of the consideration received or the fair value of the instruments issued in exchange for such services, whichever is more reliably measurable.

Recent accounting pronouncements

We do not expect that the adoption of recently issued accounting pronouncements will have a material impact on its financial position, results of operations, or cash flows. For a full summary of recent accounting pronouncements, please refer to Note 2 of Notes to Condensed Consolidated Financial Statements.

Currency exchange rates

Our functional currency is the USD, and the functional currency of our operations is the TWD. It is anticipated that all of our sales will be denominated in TWD. As a result, changes in the relative values of USD and TWD affect our reported amounts of revenues and profit (or loss) as the results of our operations are translated into USD for reporting purposes. In particular, fluctuations in currency exchange rates could have a significant impact on our financial stability. Fluctuations in exchange rates between the USD and the TWD would also affect our gross and net profit margins and could result in foreign exchange and operating losses.

Our exposure to foreign exchange risk primarily relates to currency gains or losses resulting from timing differences between the signing of sales contracts and the settling of these contracts. Furthermore, we translate monetary assets and liabilities denominated in other currencies into TWD, the functional currency of our operations. Our results of operations and cash flow are translated at average exchange rates during the period, and assets and liabilities are translated at the unified exchange rate at the end of the period. Translation adjustments resulting from this process are included in accumulated other comprehensive income in our statement of shareholders’ equity. We have not used any forward contracts, currency options or borrowings to hedge our exposure to foreign currency exchange risk. We cannot predict the impact of future exchange rate fluctuations on our results of operations and may incur net foreign currency losses in the future.

To the extent that we hold assets denominated in USD, any appreciation of the TWD against the USD could result in a charge in our statement of operations and a reduction in the value of our USD-denominated assets. On the other hand, a decline in the value of the TWD against the USD could reduce the USD equivalent amounts of our financial results.

For financial reporting purposes, the financial statements of ourthe Company’s Singapore subsidiary, which are prepared using the Singapore Dollar,SGD, are translated into the Company’s reporting currency, USD. Assets and liabilities are translated using the exchange rate on the balance sheet date, which was 0.70340.7437 and 0.72360.7325 as of March 31, 20202021 and September 30, 2019,2020, respectively. Revenue and expenses are translated using average exchange rates prevailing during each reporting period. The 0.72780.7468 and 0.7325 average0.7278average exchange rates were used to translate revenues and expenses for the six-month periodssix months ended March 31, 2021 and 2020, and 2019.respectively. Stockholders’ equity (deficiency) is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive income (loss) in stockholders’ equity (deficiency).

Not required for smaller reporting companies.

Evaluation of Disclosure Controls and Procedures

Our disclosure controls and procedures are designed to ensure that the information relating to our Company, including our consolidated subsidiaries,subsidiary, required to be disclosed in our SEC reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate to allow for timely decisions regarding required disclosure. We conducted an evaluation, under the supervision and with the participation of management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this annual report. Based on this evaluation, our chief executive officer and chief financial officer concluded that, as of the evaluation date, our disclosure controls and procedures were not effective due to material weaknesses in our internal control over financial reporting, as described below.

Management’s Report on Internal Control Over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation of management, including our chief executive officer and chief financial officer, we conducted an evaluation of the design and operating effectiveness of our internal controls over financial reporting based on the framework in “Internal Control—Integrated Framework (2013)” issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).

Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of condensed consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the condensed consolidated financial statements.

Management assessed the effectiveness of the Company’s internal control over financial reporting as of evaluation date and identified the following material weaknesses:

Inadequate Segregation of Duties: We have an inadequate number of personnel to properly implement control procedures.

Lack of Audit Committee:We do not have a functioning audit committee, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures.

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. As a result of the material weaknesses in internal control over financial reporting identified above, management concluded that the Company’s internal control over financial reporting was not effective as of March 31, 20202021 based on the criteria set forth in “Internal Control—Integrated Framework” issued by COSO.

Due to the nature of the material weaknesses, there is a more than remote likelihood that misstatements which could be material to the annual or interim financial statements could occur that would not be prevented or detected. The material weaknesses identified above either individually or in aggregation did not result in any identified misstatements or errors in the Company’s condensed consolidated financial statements as ofat and for the three-month and six-month period ended March 31, 2020.2021.

Management’s Plan for Remediation 

Management has discussed the material weaknesses noted above with our independent registered public accounting firm. Management is committed to improving its internal controls and, subject to having adequate financial resources, will (1) increase the frequency of independent reconciliations of significant accounts which will mitigate the lack of segregation of duties until there are sufficient personnel and (2) consider appointing outside directors and audit committee members in the future.

Inherent Limitations on Effectiveness of Controls

A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system’s objectives will be met. Because of its inherent limitations, internal control over financial reporting may not prevent or detect all control issues or misstatements. Accordingly, our controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our control system are met. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become adequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Changes in Internal Control

Other than any changes noted above, thereThere have been no changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II

OTHER INFORMATION

OTHER INFORMATION

We are not currently a party to any lawsuit or proceeding which, in the opinion of management, is likely to have a material adverse effect on us or our business.

Not required of smaller reporting companies.

None.Effective March 31, 2021, we issued an aggregate 6,399,965 shares of our Common Stock to certain of our directors, officers, employees and consultants, who converted accrued and unpaid compensation in the aggregate amount of $94,398. Of this amount, (i) $37,998 was with respect to amounts accrued during fiscal year 2020 and was converted at a rate of $0.05 per share into an aggregate 759,965 shares of our Common Stock; and (ii) $56,400 was with respect to amount accrued during fiscal year 2021 through March 31, 2021 and was converted at a rate of $0.01 per share into an aggregate 5,640,000 shares of our Common Stock.

On the Maturity Date of the October 2020 Loan, the noteholder converted the outstanding principal, together with accrued and unpaid interest, into 3,059,836 shares of the Company’s Common Stock at a rate of $0.01 per share.

These issuances were exempt from the registration provisions of the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof and Regulation D and/or Regulation S promulgated thereunder.

None.

Not applicable.

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

2223